- Home
- PRQR vs PLX Comparison
PRQR vs PLX Comparison
Compare PRQR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- PLX
- Stock Information
- Founded
- PRQR 2012
- PLX 1993
- Country
- PRQR Netherlands
- PLX United States
- Employees
- PRQR N/A
- PLX N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRQR Health Care
- PLX Health Care
- Exchange
- PRQR Nasdaq
- PLX Nasdaq
- Market Cap
- PRQR 224.4M
- PLX 204.9M
- IPO Year
- PRQR 2014
- PLX 1998
- Fundamental
- Price
- PRQR $2.80
- PLX $2.29
- Analyst Decision
- PRQR Strong Buy
- PLX Strong Buy
- Analyst Count
- PRQR 8
- PLX 1
- Target Price
- PRQR $8.88
- PLX $15.00
- AVG Volume (30 Days)
- PRQR 649.8K
- PLX 1.1M
- Earning Date
- PRQR 11-07-2025
- PLX 11-13-2025
- Dividend Yield
- PRQR N/A
- PLX N/A
- EPS Growth
- PRQR N/A
- PLX N/A
- EPS
- PRQR N/A
- PLX 0.08
- Revenue
- PRQR $20,129,184.00
- PLX $61,948,000.00
- Revenue This Year
- PRQR N/A
- PLX $14.53
- Revenue Next Year
- PRQR N/A
- PLX $75.77
- P/E Ratio
- PRQR N/A
- PLX $29.70
- Revenue Growth
- PRQR 8.65
- PLX 62.79
- 52 Week Low
- PRQR $1.07
- PLX $1.07
- 52 Week High
- PRQR $4.21
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- PRQR 60.30
- PLX 54.48
- Support Level
- PRQR $2.71
- PLX $2.28
- Resistance Level
- PRQR $3.00
- PLX $2.45
- Average True Range (ATR)
- PRQR 0.24
- PLX 0.16
- MACD
- PRQR 0.01
- PLX -0.02
- Stochastic Oscillator
- PRQR 71.11
- PLX 76.29
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.